FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine, namely to ophthalmology, and can be used for treatment of age-related macular degeneration. For this purpose efficient amount of antibody, which specifically binds with peptide Aβ1-40, or antibody, which specifically binds with epitope on Aβ1-40 and Aβ1-42.
EFFECT: introduction of antibodies makes it possible to recover retina functions.
13 cl, 1 tbl, 10 ex, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
| ADVANCED GLYCATION END PRODUCT (RAGE) RECEPTOR ANTIBODIES AND USING THEM | 2009 |
|
RU2518351C2 |
| BETA-AMYLOID ANTIBODIES | 2013 |
|
RU2689674C2 |
| MONOCLONAL BODY AGAINST AMYLOID BETA | 2008 |
|
RU2571856C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF | 2006 |
|
RU2432362C2 |
| HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE | 2020 |
|
RU2783528C1 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
